ArticleMolecular biology reports2026
A de novo NR2F1 c.330 C > A variant in Bosch-Boonstra-Schaaf optic atrophy syndrome presenting with early-onset developmental and epileptic encephalopathy.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) is a rare autosomal dominant neurodevelopmental disorder caused by pathogenic variants in the NR2F1 gene. The syndrome is characterized by a complex phenotype including optic nerve atrophy, global developmental delay, intellectual disability, and seizures. We report a patient with this syndrome whose prominent clinical presentation included developmental and epileptic encephalopathy (DEE). Due to overlapping clinical features with other neurodevelopmental disorders, clinical diagnosis remains challenging, necessitating molecular genetic studies. PATIENT PRESENTATION: The proband was a 14.5-month-old female who presented with early-onset neurological symptoms, including severe hypotonia, global developmental delay, drug-resistant seizures, bilateral optic atrophy, hearing loss, and structural brain anomalies. METHODS AND
resultsWhole-exome sequencing (WES) revealed two novel heterozygous variants: a nonsense variant in ARF3 (NM_001659.3:c.295C>T, p.Arg99*) and a missense variant in NR2F1 (NM_005654.6: c.330C>A, p.Phe110Leu). Sanger sequencing segregation analysis demonstrated that the ARF3 variant was inherited from the clinically unaffected father, indicating it is unlikely to be the primary causative variant. In contrast, the NR2F1 variant was confirmed to be de novo. The NR2F1 variant was absent in a local control cohort of 500 healthy individuals and in major population databases.
conclusionThe novel NR2F1 variant was classified as likely pathogenic according to ACMG guidelines, confirming the diagnosis of BBSOAS. The ARF3 variant, identified as a secondary finding of uncertain clinical significance, is unlikely to account for the patient's phenotype; however, reporting this variant may facilitate future interpretation of ARF3-associated disease. This is the first reported case of BBSOAS in an Iranian patient.
Indexed as
Identifiers
42606787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.